XprecisPrime™

Next generation CLIA waived point of care PT/INR analyzer

High performance across the therapeutic range

Data obtained from independent FDA 510(k) equivalence study.
CLIA waiver approved for POC use without requirement for specialist training.1

Laboratory Reference INR Range	Allowable Difference	Percentage within allowable difference	
		UBI: Xprecia Prime2	Roche Coaguchek3
0 to 1.9	± 0.4 INR	98.30%	97.13%
2 to 3.5	**± 20% INR**	**97.70%**	**82.31%**
3.6 to 4.5	± 20% INR	91.80%	85.71%
Total	-	97.18%	90.09%

1 FDA 510 (k) CLIA waiver https://www.accessdata.fda.gov/cdrh_docs/clia_waivers/CW230004.pdf. date of access 19.07.2024
2 Xprecia Prime Allowable Difference Acceptance Criteria for all Evaluable Subjects (including outliers) all study sites – N = 355 patients
3 Roche Coaguchek Allowable Difference Acceptance Criteria for all Evaluable Subjects (including outliers) all study sites – N = 353 patients

- Easy finger-to-strip application
- No calibration chips required
- Accurate testing in 5 steps
- Strip eject button for safer waste disposal

Register your interest

Trust Xprecia Prime™ to provide reliable results every time. Request a demo and see the difference!

Xprecia Prime™

XpreciaSales@universalbiosensors.com
Phone: +1 302 366 2723

Results in less than 1 minute

5 SIMPLE STEPS

Scan patient ID

Scan test strip

Insert test strip

Apply sample

Results shown

Register your interest at: XpreciaSales@universalbiosensors.com

Xprecia Prime
W: www.universalbiosensors.com/products/xprecia/
E: XpreciaSales@universalbiosensors.com

POWERED BY Universal Biosensors

20240712C